Health Care

Calidi Biotherapeutics unveils its RedTail virotherapy platform, a targeted gene‑therapy breakthrough for solid tumors, advancing IL‑15 and T‑cell engagers toward clinical trials.

OSR Holdings Inc. (OSR) is a blank‑check company targeting growth in healthcare. With a volatile stock yet a clear acquisition strategy, it offers investors a chance to profit from future buyouts in the rapidly evolving healthcare sector.

Explore Amylyx Pharmaceuticals’ strategic move to the 25th Annual Needham Virtual Healthcare Conference, highlighting its ALS research, investor outreach, and future prospects.

Ardelyx’s new partnership and promising preclinical data signal a boost for its mineral‑metabolism drugs, while disciplined capital strategy keeps investors focused on long‑term growth.

Johnson & Johnson stock steadies at $241.3, eyes a $251.71 52‑week high, amid mixed institutional trades and fresh earnings forecasts.

Dexcom’s Q2/Q3 2025 earnings reveal steady revenue growth, margin improvement, and robust R&D, but investor sentiment warns of pricing, reimbursement, and competition risks.

VG Life Sciences Inc. pioneers breakthrough therapies for cancer, infections and autoimmune diseases—small cap, big impact on patient care and biotech innovation.

Recordati faces a €10.9 bn takeover bid from CVC Capital, sparking a market sell‑off and raising questions on valuation, debt, and future R&D synergies.

Milestone Pharmaceuticals’ upcoming presentation at the Needham Virtual Healthcare Conference highlights its CARDAMYST® nasal spray and innovative cardiovascular pipeline, offering investors fresh insight into the company’s growth potential and mark…

Onco‑Innovations expands in Australia, partnering with RDI Partners and forming a local subsidiary to fast‑track Phase I oncology trials while leveraging 43.5% R&D tax credits.